Home / Pharmaceuticals / Parkinson’s Disease Therapeutics: Market Growth, Future Prospects & Competitive Analysis, 2016-2024

Parkinson’s Disease Therapeutics: Market Growth, Future Prospects & Competitive Analysis, 2016-2024

Overview:

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of the central nervous system characterized by tremor, rigidity, postural instability, and hypokinesia. A patient’s brain slowly stops producing a neurotransmitter called dopamine, it sends messages to the part of the brain that controls movement. PD is not fatal disease but complications from this disease are more serious. According to Centers for Disease Control and Prevention (CDC) in year 2013 PD is the 14th top cause of death in the United States. According to World Health Organization (WHO) PD is a universal disorder, with a crude incidence rate of 4.5–19 per 100,000 population per year. According to the Parkinson's disease Foundation, PD affects about 1 million people in the United States and more than 4 million people worldwide. About 60,000 people are diagnosed each year in the United States. Men develop the disease slightly more often than women. PD is rare in people younger than 30 years of age, and risk for the disease increases with age.

Currently, there is no cure for PD, but medications provide relief from the symptoms. Anti-Parkinson’s medications are categorized on the basis of drug class such as Levodopa therapy, Dopamine Receptor Agonists (pramipexole or apomorphine), Anticholinergics (benztropine or trihexyphenidyl), MAO-B Inhibitors (rasagiline or selegiline), COMT Inhibitors (entacapone, tolcapone) and Other Therapeutic Options (Amantadine or Droxidopa). Levodopa (Sinemet) is the most effective and most commonly prescribed drug for controlling the symptoms of PD. Dopamine agonists (Requip or Mirapex) are generally prescribed as first line therapy and levodopa is given to  the patient's if the symptoms cannot be controlled sufficiently. Anticholinergics (Artane, Cogentin) are rarely used. In some cases, surgery performed if the disease doesn't respond to medication. A therapy, deep brain stimulation now approved by the U.S. Food and Drug Administration.

The major growth drivers of the PD market includes, rising male population worldwide, increasing an aging population that will increase prevalence of PD, increased patient compliance, technological advances and innovation. Major barriers of growth for the global PD market are lack of novel therapeutic classes, increase competition from generic versions.

Companies such as, Novartis AG, GlaxoSmithKline Plc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceutical International, UCB, Abbvie Inc., Impax Labs, Lundbeck are involved in manufacturing of Anti-Parkinson’s medication. America’s biopharmaceutical research companies are currently developing 37 new medicines to treat PD. Major players having drugs in the pipeline are Novartis AG, Pfizer, Inc., Ceregene, Inc., GlaxoSmithKline Plc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., UCB, Biogen, Roche, Abbvie Inc., Impax Labs, Lundbeck, Orion Corp, Newron Pharmaceuticals and Others.

The Global Parkinson’s Disease Therapeutics Market is segmented on the following bases:

  • Global Anti-Parkinson’s drugs Market Revenue (USD Mn), By drug class type, 2016-2024
    • Levodopa therapy
    • Dopamine Receptor Agonists
    • Anticholinergics
    • MAO-B Inhibitors
    • COMT Inhibitors
    • Other Therapeutic Options
  • Global Anti-Parkinson’s drugs Market Revenue (USD Mn), By Geography, 2016-2024
    • North America
      • US
      • Canada
    • Europe
      • UK
      • Germany
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • Rest of APAC
    • Latin America
    • Middle East and Africa

Key Players Identified for Parkinson’s Disease Therapeutics Market Include:

Novartis AG, GlaxoSmithKline Plc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., UCB, Biogen, Roche, Abbvie Inc., Impax Labs, Lundbeck, Orion Corp, Newron Pharmaceuticals and Others.

This report offers:

  • An overview of the global markets for Parkinson’s Disease Therapeutics
  • Market trends assessment for the period 2014-2024, with historical information for 2014 & 2015, and projections through 2024, with respective CAGRS during 2016-2024
  • Qualitative assessment tools such as market drivers, challenges and future prospects.
  • Market competition scrutiny tools such as market share analysis, fractal map assessment.
  • Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
  • A general overview of the industry structure
  • Company profiles highlighting key information about the major players operating in the Parkinson’s Disease Therapeutics Market
Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients